A note about WF10...
The information that's being posted is information. It's not an inducement. Nobody's advising you to buy.
Research has still not isolated the exact mechanisms that are at work. They're complex and basic, local and systemic, all at the same time.
Discussing WF10 with another investor, I estimated it would take 200 researchers to "bring WF10 home".
Despite the controversy about the P3, I still feel it was the best shot at getting WF10 to the front of the pack. It was (and is) an attempt to show that the stuff works - even in patients with severely compromised immune systems - patients who are terminally ill.
In a sense, the WF10 P3 is a "hail-Mary pass" - a long shot. But it was the long shot with the best possible chance of success. That said, there's no question, even if the P3 succeeds, that research will have to continue.
That possibility has been discussed publicly, as has the intention - the necessity - to partner development.
The reference to WF10 "tire-kickers" was probably accurate: but the tire-kicking will be much more enthusiastic after a successful P3.
So, this information is designed to for those Dimethaid investors who really aren't sure about WF10. Is it real, or is it just an illusion?
IMO, it's very real - it has demonstrated potential, and there's a tremendous amount of research that's starting to zero in on its central mechanisms. But it's not without risk. Be aware of these things when you read WF10 material.
Jim |
